GALIG Gene Expression in Parkinson's Disease

Parkinson Disease Clinical Trial

— GALIGPARK  

Official title:

GALIG Gene Expression in Parkinson's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02923297
• Other study ID #: CHRO-2014-05
• Status: Completed
• Phase: N/A
• Start date: April 2015
• Est. completion date: June 30, 2015

Study information

• Verified date: August 2020
• Source: Centre Hospitalier Régional d'Orléans
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Parkinson's disease (PD) is the most frequent neurodegenerative disorder after Alzheimer's disease. It is characterized by motor symptoms (rigidity, tremor, slowness of movements), and non-motor symptoms (neuropsychological, psychiatric, pain ...). Neuronal death initiates in the brainstem and extends progressively through the entire cortex. The processes leading to cell death are poorly understood. Pathological cells exhibit abnormal deposits, called Lewy bodies, which contain numerous proteins. A major constituent of these protein deposits is alpha-synuclein. It has recently been demonstrated, in the Laboratory of Molecular Biophysics of the CNRS (Scientific Research National Center) in Orleans, that α-synuclein interacts with Cytogaligin, a protein produced by the proapoptotic GALIG gene. Cytogaligin could thus be a factor regulating α-synuclein activity or aggregation. It is postulated that the level of expression of the GALIG gene is different in Parkinson's disease patients compared with control subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: June 30, 2015
• Est. primary completion date: June 30, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with Parkinson's Disease according to the criteria of the UKPDBB (UK Parkinson's disease brain bank).

Exclusion Criteria:

• Insane patient arriving without a third party.

• Patient with Parkinson's disease arising from another etiology.

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Other:
• Blood sampling
blood sampling for determine and compare the expression patterns of GALIG gene

Locations

Country	Name	City	State
France	CHR d'ORLEANS	Orleans

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Régional d'Orléans	National Scientific Research Centre

Country where clinical trial is conducted

France, 

References & Publications (3)

Alieva AKh, Filatova EV, Karabanov AV, Illarioshkin SN, Slominsky PA, Shadrina MI. Potential Biomarkers of the Earliest Clinical Stages of Parkinson's Disease. Parkinsons Dis. 2015;2015:294396. doi: 10.1155/2015/294396. Epub 2015 Sep 21. — View Citation

Pinho R, Guedes LC, Soreq L, Lobo PP, Mestre T, Coelho M, Rosa MM, Gonçalves N, Wales P, Mendes T, Gerhardt E, Fahlbusch C, Bonifati V, Bonin M, Miltenberger-Miltényi G, Borovecki F, Soreq H, Ferreira JJ, F Outeiro T. Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. PLoS One. 2016 Jun 20;11(6):e0157852. doi: 10.1371/journal.pone.0157852. eCollection 2016. Erratum in: PLoS One. 2017 Dec 28;12 (12 ):e0190552. — View Citation

Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):955-60. Epub 2007 Jan 10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	RNA (ribonucleic acid) assay of GALIG gene	Only one assessment in the study	Day 0
Primary	RNA (ribonucleic acid) assay of SNCA genes	Only one assessment in the study	Day 0